-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The COVID-19 new crown pneumonia pandemic caused by the new coronavirus SARS-CoV-2 has brought great negative effects on human medical treatment, economy and life.
is significant and challenging how to respond quickly to the oncoming COVID-19 new crown pneumonia and potential new epidemic diseases.
previous studies have shown that the new coronavirus SARS-CoV-2 relies on human angio tension conversion enzyme II (ACE2) to enter the host cell.
in response to the virus's entry and infection, the host immune system raises inflammatory cytokines to remove the invading virus and promote tissue repair.
, the body continues to maintain high levels of inflammatory cytokines (known as "cytokine storms"), which can lead to systemic immune dysfunction.
, in addition to vaccine research and development, blocking the entry of viruses and suppressing "cytokine storms" is also the focus of COVID-19 research.
of antiviral drugs, including Redsyvirus, are actively conducting clinical trials, and early intervention in new coronavirus SARS-CoV-2 infections has shown encouraging results.
, however, there are very few candidates for severe infections.
some preclinical and clinical studies have reported that monoclonal antibodies targeting lebines-6 (IL-6) and granulocyte-macrophage collection stimulation factors (GM-CSF) may inhibit the "cytokine storm" caused by the new coronavirus SARS-CoV-2.
, however, systematic control of cytokine storms remains challenging due to the diversity of cytokine species and the complexity of the interactions between cytokines.
recently, Professor Chen Xiaoyuan of the National Institutes of Health and a team of professors Jiang Shib, Xie Yuhua and Lu Lu of Fudan University jointly published a research paper entitled: Decoy nanoparticles protection against COVID-19 by concurrently adsorbing viruses and cytokines.
for the first time, the study used genetically engineered cell membrane nanocystic bubbles to act as "baits" to compete with host cells, able to adsorb both viral and inflammatory cytokines, effectively protecting host cells from COVID-19 coronary pneumonia.
In order to build nano-baits, the team first trans-dyed high-expression ACE2 subjects on 293T cells, then isolated the cell membrane nanocysts from engineered 293T/ACE2 and THP-1 cells, and finally mixed the alien nano-vesicles to obtain nano-baits.
nano-bait inherits the rich ACE2 and cytokine subjects on the surface of the source cells and is able to mediate both viral and inflammatory cytokines, thus effectively interfering with COVID-19 neocyto pneumonia infection.
at the cellular level, the team tested that nano-baits can compete with host cells, effectively adsorbing and suppressing infections of host cells by multiple fake viruses.
further, based on the new SARS-CoV-2 coronavirus, the team found that nano-baits can significantly reduce viral particles, lower viral RNA levels, and inhibit viral infections.
based on small animal models of acute pneumonia, the researchers further verified that nano-bait effectively adsorption of multiple cytokines and effectively reduced inflammatory IL-6 and GM-CSF levels in lung irrigation lotions.
the acute inflammation of the lungs in mice was well relieved by inhaling nano-baits into the nose.
the study showed a new nanotechnology for alleviating the immune disorder caused by COVID-19 neo-crown pneumonia, providing a new research idea for the treatment of COVID-19 new coronary pneumonia.
Professor Chen Xiaoyuan of the National Institutes of Health and Professors Jiang Shib, Xie Yuhua and Lu Lu of Fudan University are co-authors of this paper, and Rao Lang, a postdoctoral fellow at the National Institutes of Health, Xia Shuai, a postdoctoral fellow at Fudan University, and Xu Wei, a young associate researcher, are co-authors of the paper.
.